Skip to main content
PrintBio is a privately held, clinical- and commercial-stage biotechnology company and leader in regenerative medicine using novel 3D-bioprinting and material science technologies to deliver safe, functional and personalized products and living tissues and organs, engineered and produced on-demand for patients.  The Company was founded and is led by an experienced team of biotechnology founders and executives.

 

For questions regarding investment opportunities, email: investors@printbio.com

Learn More

Brent Saunders Appointed as Advisory Board Chairman

| News, Press Releases | No Comments
Saunders was previously CEO of Allergan, the company that developed and launched Botox™ until the company’s $63 billion acquisition by AbbVie Inc. in 2020 Miami, FL – February 26, 2025…

Brent Saunders Appointed as Advisory Board Chairman

| News, Press Releases | No Comments
Saunders was previously CEO of Allergan, the company that developed and launched Botox™ until the company’s $63 billion acquisition by AbbVie Inc. in 2020 Miami, FL – February 26, 2025…

PrintBio Receives FDA Clearance for 3DMatrix™, the First 3D-Printed Resorbable Surgical Mesh 

| News, Press Releases | No Comments
PrintBio Receives FDA Clearance for 3DMatrix™, the First 3D-Printed Resorbable Surgical Mesh PrintBio was founded by Rapha Capital Management, LLC and its investors through its SPV, Rapha Capital Investment XIV,…